Skip to content
TWhen you hear the term digital therapeutics, the first thing that comes to mind is mental health apps, CBT platforms, or digital tools for anxiety, depression, and sleep. And yes, that part of the market is what defined the category early on.
But in the past couple of years, it has become clear that digital therapeutics is beginning to stretch well beyond mental health. Diabetes, for instance, has already emerged as an important area of interest, with recent research exploring the potential of digital therapeutics in diabetes management.
That made us wonder: could this be happening in other parts of healthcare too?
To understand where this innovation is heading, we used InspireIP’s embedded prior art search engine, powered by PQAI. This article uncovers the trends we saw emerging from the patent dataset.
Our Methodology
To understand where digital therapeutics innovation is heading beyond mental health, we ran the following query:
Digital systems and software platforms used to deliver therapeutic interventions, treatment support, or disease management for a wide range of medical conditions, without relying only on drugs or invasive procedures.
We intentionally kept the query broad to avoid restricting the search to mental health alone. Our goal was to identify which treatment-focused software systems were emerging across the broader therapeutic landscape.
To keep the analysis focused on recent developments, we then narrowed the results to recent patent filings from 2024 onward during our review. That helped us look more closely at where innovation appears to be moving now, rather than relying too heavily on older filings. Here’s what the trends looked like.
5 Trends Emerging in Digital Therapeutics Beyond Mental Health
When we reviewed the patent filings, a few interesting patents began to appear from areas like oncology and broader clinical decision support. But as we looked deeper, a different set of patterns started to stand out more clearly.
We noticed that inventors are filing around chronic pain, diabetes management, and long-term treatment orchestration. Not just that, there was also activity around AI-guided therapy planning, rehabilitation decision systems, and platforms designed to measure whether a treatment is actually working.
These trends indicate how digital therapeutics is evolving beyond a narrow category of therapy apps and into a broader domain built around software, data, personalization, and ongoing intervention. Here are the five innovation trends that stood out most in the patent data.
Trend 1: Digital therapeutics is moving into long-course chronic care
When we looked at the patent data, one thing became clear. Diabetes is not the only area where digital therapeutics is beginning to grow. There is also visible activity around chronic conditions, where treatment is rarely linear and needs constant updating with time.
In fact, the filings are not just about digitizing treatment plans. They are trying to make chronic care easier to manage when the journey with the disease is long, messy, and constantly changing. Here are a few patents that stood out to us.
Cerner Innovation, now acquired by Oracle, filed a patent application around managing active treatments for patients suffering from more than one ailment. While electronic health records can help treatment providers access a patient’s full medical history, there are times when providers do not have time to review the patient’s history and must focus on the current ailment.
That is when the system described in patent application US20250166771A1 helps surface treatment options, making it easy for healthcare providers to quickly administer treatment based on the current condition.
Then there is US20250285764A1 filed by pharma company Sequelae, which links intervention decisions to biological marker levels. In simple terms, the patent application is around deciding when an intervention may be needed based on what is happening in the patient’s body. Now that intervention could be a suggestion, either in the form of changing drugs or lifestyle changes.
These and the other filings suggest that digital therapeutics is evolving into something much broader than a digital application.
It is becoming a more adaptive treatment layer for chronic conditions, and there is definitely a lot of scope for innovation if you are working on any of these areas.
Trend 2: Digital therapeutics is getting much more serious about diabetes care
When we were going through these filings, diabetes stood out as one of the strongest clusters.
It was not at all surprising. Diabetes is one of the clearest use cases for software-led intervention because with the availability of wearables, there is continuous data being generated. Moreover, the condition often requires active intervention rather than occasional check-ins.
However, what stood out to us was the kind of problems these patents were trying to solve.
For instance, US2025235155A1, which is filed by the University of Virginia Patent Foundation, is trying to make diabetes management feel less fragmented.
Right now, monitoring glucose levels, risk assessment, advice, and treatment adjustment often sit across different tools or systems.
What this patent is trying to do is bring all of that together into one platform. The platform can spot long-term trends and enable real-time automated glucose control. The beauty of this is that it is trying to create a more connected treatment environment where monitoring, control, and intervention can all work together.
In fact, one reason that makes innovation in this area important is how much change digital therapeutics can make here. It is moving toward treatment-linked systems that are more physiological, more intervention-aware, and much closer to real treatment support.
Trend 3: Pain management and rehabilitation are becoming important digital therapeutics areas
Another clear pattern in the data was the emergence of digital therapeutics for chronic pain and rehabilitation.
This is an important trend because pain remains one of the biggest areas where healthcare professionals are looking for effective non-drug interventions. It is also one of those areas where rehabilitation often becomes important, which is what makes this cluster interesting.
One of the clearest examples here is CN119314705A. The filing describes a digital therapy system for chronic pain, What makes it notable is that it connects doctor-patient communication, treatment plan submission, remote guidance, process monitoring, and treatment-effect reporting all within one system. But for Chronic pain.
There is also another Chinese filing, CN119339919A, which reflects a similar movement. The patent is trying to make rehabilitation more structured by taking in patient information, recommending a prescription, evaluating treatment effect, and then adjusting the prescription if the expected result is not achieved.
There are other US-based patent applications too, like US2025210169A1, that fit this pattern. What stands out across these filings is the shift from basic tracking to digitally guided intervention.
The software is not there simply to record symptoms. It is there to help shape the treatment path. And in this case, that treatment path is not just about managing pain, but also about supporting rehabilitation where recovery needs to be guided over time.
Trend 4: AI is starting to shape treatment inside digital therapeutics
One of the strongest and most repeated signals we came across was the use of AI to personalize treatment.
AI is everywhere, and personalization is happening at multiple levels. In your ChatGPT responses, or how AI Overviews bring data to you when you ask for innovation trends in digital therapeutics. And the patent data suggests that AI is going much deeper. It is being used to understand treatment better, optimize it, personalize it, and even communicate it more effectively to patients.
A few patents from our search reflected that clearly:
- US12374441B2 describes a system that uses AI to determine whether autism treatment sessions are being carried out as intended. Instead of just recording what happened, the patent looks at how closely the treatment was followed, and then uses that along with other patient and session data to help improve clinician feedback and the next steps in treatment.
- US2025285729A1, assigned to Ainnocence, does something different. It uses patient multiomics data and genomic variant analysis to recommend therapies. This is a more data-heavy layer where AI is being used to help decide which therapy may fit a patient best based on what is happening biologically.
- US2025269233A1, filed by Sword Health, is another interesting application, because it uses real-time performance data such as range of motion, exercise completion, and movement accuracy, along with historical context, to generate personalized messages during therapy sessions.
One thing is clear. AI is not just being added as a support feature. It is starting to shape the therapeutic layer itself and it remains to be seen what else evolves here.
Trend 5: Digital biomarkers may become the next layer in digital therapeutics
Given the pace at which AI is advancing, there also needs to be better ways to read what is actually happening with the patient over time. That is where digital biomarkers and patient-state signals start to become important.
The good news is that work is going on in this area as well.
One patent that really stood out here was US20250248661A1 by Beneufit Inc. It focuses on creating digital movement biomarkers from video data using self-supervised learning.
In simple terms, the system is trying to look at how a person moves, pull out kinematic data from their movement. They then turn that into a biomarker profile that can help track symptoms, disease progression, and even the impact of treatment more objectively.
What makes this interesting is that it is trying to move beyond subjective observation and make treatment monitoring more measurable, especially in areas like rare diseases and movement disorders.
Then there is US20250210169A1 by Micron Technology, which takes a slightly different route. Rather than relying on clinical inputs alone, it considers how the person is behaving, what patterns are showing up, and how multiple signals can come together to guide the next step.
What stands out across these filings is that digital therapeutics may start depending less on self-report alone and more on signals that can be continuously observed, measured, and interpreted.
And if that happens?
This becomes one of the most interesting areas to watch because it changes how treatment is not just delivered, but also understood.
Looking at the recent filings, one thing becomes clear. Digital therapeutics is moving beyond its early identity of guided mental health support or digital behavior change tools. It is expanding into areas where software can help manage treatment over time, interpret physiological and behavioral data, personalize interventions, and even measure whether those interventions are delivering value.
That does not mean every patent in this space is a pure digital therapeutic. The dataset still includes adjacent systems, and some filings lean more toward treatment management or clinical infrastructure than productized DTx in the strict sense.
But the direction is clear. The category is widening. And there is lots of scope for innovation for companies building in this space.
Explore Digital Therapeutics Innovation with InspireIP
Digital therapeutics is clearly moving into new territory. If you are building in this area, whether as a digital health company, care platform, medtech team, or healthcare innovator, it becomes important to capture these ideas early.
Because many of the most valuable invention opportunities do not always arrive as big breakthroughs. Sometimes, they show up as a better treatment workflow, a smarter intervention layer, or a more effective way to personalize and measure care.
The challenge is that these ideas often emerge during product development, clinical work, or day-to-day problem-solving. Without a structured system to capture them, they can easily get missed.
That is where InspireIP’s IPAssist can help.
With InspireIP, teams can capture invention ideas as they emerge, explore prior art using its built-in patent search engine, powered by PQAI, and understand how their ideas compare with what already exists.
That makes it easier to spot whitespace, strengthen invention disclosures, and move faster on ideas that are actually worth protecting. If you are working on digital therapeutics, this is a good time to put that process in place.
Want to know more about the tool? Request a demo here.
